Sartorius Aktiengesellschaft (SOAGY)
| Market Cap | 19.49B +12.2% |
| Revenue (ttm) | 4.16B +4.2% |
| Net Income | 248.13M +63.5% |
| EPS | n/a |
| Shares Out | n/a |
| PE Ratio | 78.56 |
| Forward PE | 41.95 |
| Dividend | 0.17 (0.27%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 3,657 |
| Open | 62.98 |
| Previous Close | 61.63 |
| Day's Range | 62.75 - 63.26 |
| 52-Week Range | 46.97 - 63.26 |
| Beta | 1.45 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 22, 2026 |
About SOAGY
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems; cell culture solutions, including bioreactors and fermenters, cell culture reagents, supplements and matrices, nucleic acid and delivery solutions, cell culture... [Read more]
Financial Performance
In 2025, SOAGY's revenue was 3.54 billion, an increase of 4.66% compared to the previous year's 3.38 billion. Earnings were 154.90 million, an increase of 84.40%.
Financial numbers in EUR Financial StatementsNews
Sartorius Aktiengesellschaft Earnings Call Transcript: Q3 2026
Nine-month growth and profitability advanced across both divisions, with stronger cash generation and lower leverage. FY guidance was confirmed, with LPS raised; Q3 pull-forward, tariff headwinds and tough Q4 comparisons temper near-term growth.
Sartorius Aktiengesellschaft Earnings release: Q3 2026
Sartorius Aktiengesellschaft released its Q3 2026 earnings on October 22, 2026, summarizing the period's financial results.
Sartorius Aktiengesellschaft Slides: Q3 2026
Sartorius Aktiengesellschaft has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 22, 2026.
Sartorius Aktiengesellschaft Earnings Call Transcript: Q2 2026
Solid operational growth and improved profitability were achieved in H1 2026, with strong cash flow and robust demand for consumables. Guidance for full-year revenue and margin was confirmed, while tariff-related effects and delayed advanced therapy orders remain key uncertainties.
Sartorius Aktiengesellschaft Earnings release: Q2 2026
Sartorius Aktiengesellschaft released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
Sartorius Aktiengesellschaft Quarterly report: Q2 2026
Sartorius Aktiengesellschaft has published its Q2 2026 quarterly earnings report on July 23, 2026.
Sartorius Aktiengesellschaft Slides: Q2 2026
Sartorius Aktiengesellschaft has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 23, 2026.
Sartorius beats half-year earnings expectations
German pharmaceutical company Sartorius reported half-year earnings slightly above market expectations on Thursday, citing stable recurring business and the effect of U.S. tariff refunds.
Sartorius Aktiengesellschaft Earnings Call Transcript: Q1 2026
Sales and recurring business grew strongly in Q1 2026, with EBITDA margin resilient and cash flow up. Guidance for 2026 is confirmed, expecting 5%-9% sales growth and continued deleveraging, despite FX and geopolitical risks.
Sartorius Aktiengesellschaft Earnings release: Q1 2026
Sartorius Aktiengesellschaft released its Q1 2026 earnings on April 23, 2026, summarizing the period's financial results.
Sartorius Aktiengesellschaft Slides: Q1 2026
Sartorius Aktiengesellschaft has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 23, 2026.
Sartorius Aktiengesellschaft Transcript: AGM 2026
AGM highlighted strong 2025 financial results, strategic acquisitions, and investments in innovation and sustainability. Leadership changes and refined strategy focus on portfolio, customer experience, and operational excellence. Dividend of EUR 0.73/0.74 per share proposed.
Sartorius Aktiengesellschaft Transcript: CMD 2026
Ambitious midterm targets include 8%-11% organic revenue growth and 50-75 bps annual EBITDA margin expansion, driven by innovation in single-use technologies, advanced therapies, and digitalization. U.S. and Asia are key growth regions, with operational excellence and disciplined capital allocation supporting sustainable value.
Sartorius Aktiengesellschaft Press release: FY 2026
Sartorius Aktiengesellschaft issued a press release on March 17, 2026, disclosing material business information to investors.
Sartorius Aktiengesellschaft Slides: FY 2026
Sartorius Aktiengesellschaft has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 17, 2026.
Sartorius Aktiengesellschaft Earnings Call Transcript: Q4 2025
2025 saw robust growth driven by recurring business, with sales up 7.6% in constant currency and EBITDA margin at 29.7%. Guidance for 2026 anticipates 5%-9% sales growth and margin above 30%, supported by innovation, capacity expansion, and a strong order book.
Sartorius Aktiengesellschaft Earnings release: Q4 2025
Sartorius Aktiengesellschaft released its Q4 2025 earnings on February 3, 2026, summarizing the period's financial results.
Sartorius Aktiengesellschaft Slides: Q4 2025
Sartorius Aktiengesellschaft has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 3, 2026.
Sartorius Aktiengesellschaft Annual report: Q4 2025
Sartorius Aktiengesellschaft has published its Q4 2025 annual report on February 3, 2026.
It's time to scoop up undervalued stocks in this critical sector of the economy
Expanding your horizons and considering neglected sectors can help you identify bargain opportunities while defending your investment portfolio from a stock-market decline.
Sartorius Shares Rise After Guidance Lift
Sartorius said it now expects 7% revenue growth for 2025, compared with 6% previously, as underlying net profit rose 17%.
Betting on Growth: 4 Favorite Stocks From T. Rowe Price's Peter Bates
The manager of the Global Select Equity Strategy looks for high margins, cash generation, competitive advantages, and a long runway of growth.
10 stocks for investors looking for ‘wonderful companies at a fair price'
As money managers talk about various methods of selecting quality companies, investors might also think about diversification, which can lower risk and broaden opportunities.
These 5 DAX index companies are in trouble as their stocks plunge
German stocks are not doing well as the economy goes through substantial challenges. The most recent data showed that business confidence has tumbled while manufacturing and services PMIs have remaine...
Sartorius, Sartorius Stedim shares fall after Polyplus acquisition
Shares in German pharmaceutical and laboratory equipment supplier Sartorius AG and its France-listed subsidiary Sartorius Stedim Biotech SA DIM, -6.51% fell in opening trade on Friday after the compan...